News
Calidi Biotherapeutics
CLDI · NYSE American
$0.77−$0.0134 (−1.71%)TodayMarket closed ·
Prev close $0.7834
Latest news
- Press releaseGlobe Newswire
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Press releaseGlobe Newswire
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
- News
Calidi Biotherapeutics Receives Pre-IND Regulatory Feedback From FDA Providing Alignment, Clarity On IND-Enabling Preclinical Plans And Clinical Strategy For CLD-401 Prior To Advancing Drug Candidate Into Phase 1 Clinical Studies
- Press releaseGlobe Newswire
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
- Press releaseGlobe Newswire
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
Calidi Biotherapeutics Collaborates With TransferAI To Advance Its IND Submission For CLD-401 By Using The Sofie Proprietary Agentic AI Platform
- Press releaseGlobe Newswire
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
- News
Calidi Biotherapeutics Partners With Avance Clinical On Initiating First-In-Human Clinical Trial For CLD-401 In Australia
- Press releaseGlobe Newswire
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials
- NewsAvi Kapoor
Crude Oil Jumps Over 12%; US Retail Sales Fall In January
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Nasdaq Down Over 300 Points; US Economy Loses 92,000 Jobs In February
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- Press releasePRNewswire
Matica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward IND
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Nasdaq Down 1%; Lowe's Posts Upbeat Earnings
- NewsAvi Kapoor
Dow Surges 100 Points; Target Shares Fall After Q2 Results
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releasePRNewswire
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
- Press releaseGlobe Newswire
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
- Press releaseGlobe Newswire
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
- NewsAvi Kapoor
Crude Oil Moves Higher; RxSight Shares Plunge
- NewsAvi Kapoor
Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May
- Press releasePRNewswire
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
- NewsMohd Haider
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On
- Press releaseGlobe Newswire
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
- Press releasePRNewswire
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
- Press releasePRNewswire
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseGlobe Newswire
Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma
- NewsHenry Khederian
Why Calidi Biotherapeutics (CLDI) Stock Is Down 30%
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.